Acute Cardiotoxic Effects of Adjuvant Trastuzumab Treatment and Its Relation to Oxidative Stress
Authors:
- 26 February 2014
- journal article
- research article
- Published by SAGE Publications in Angiology
- Vol. 65 (10) , 944-949
Abstract
Our aim was to evaluate the acute cardiac toxicity of adjuvant trastuzumab treatment and its possible relation to changes in oxidative stress. Electrocardiographic and echocardiographic tissue Doppler imaging (TDI) parameters, activity of antioxidant enzymes (superoxide dismutase; SOD), and products of oxidative stress (malondialdehyde; MDA) were analyzed in 30 patients with early-stage breast cancer who had adjuvant trastuzumab treatment. There was a significant prolongation of QT interval after trastuzumab treatment. There was also a significant decrease in left ventricular ejection fraction (LVEF), TDI-derived S’ parameters, and SOD enzyme activity and increase in MDA levels after trastuzumab infusion. There was a positive correlation between changes in SOD activity and LVEF and a negative correlation between changes in MDA levels and LVEF. This study demonstrated a correlation between decreases in LVEF and increases in products of the oxidative stress in patients who had adjuvant trastuzumab treatment.Keywords
This publication has 22 references indexed in Scilit:
- Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: a pilot studyMedical Oncology, 2012
- Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) TrialJournal of Clinical Oncology, 2010
- Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical TrialsJournal of Clinical Oncology, 2010
- Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast CancerAmerican Journal of Surgical Pathology, 2009
- Long-Term Cardiac Tolerability of Trastuzumab in Metastatic Breast Cancer: The M.D. Anderson Cancer Center ExperienceJournal of Clinical Oncology, 2006
- HER-2 Testing in Breast Cancer Using Parallel Tissue-Based MethodsJAMA, 2004
- HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer TissuesClinical Breast Cancer, 2004
- Clinical Cardiac Tolerability of TrastuzumabJournal of Clinical Oncology, 2004
- Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinasesNature, 1997
- Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.Journal of Clinical Oncology, 1990